Previous 10 | Next 10 |
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double visio...
-- Text the word “EYE” to 56512 to generate a donation from Horizon to Prevent Blindness to fund TED education -- Today, in support of World Sight Day, Horizon Therapeutics plc (Nasdaq: HZNP) and Prevent Blindness launched a campaign that brings together the voices of t...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating r...
Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scie...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the top 100 adoption-friendly workplaces in the country by the Dave Thomas Foundation for Adoption, ranking number 56 overall and number 2 in the pharmaceutical category. The list recognizes organizations wi...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Outperform rating and $146 (45% upside) price target at William Blair. More news on: Alexion Pharmaceuticals, Inc., Change Healthcare Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with this Read more ...
ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Buy rating and $76 (9% upside) price target at Guggenheim. More news on: ANI Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Lately, recession signals seem to be popping up daily. Risk averse investors may find it wise to start preparing for the possibility of an economic downturn. Horizon Therapeutics ( HZNP ) is one option as an equity that is resistant to the business cycle fluctuations and is poised to continue ...
Under Priority Review status, the FDA has accepted for review Horizon Therapeutics' ( HZNP -2.6% ) marketing application for teprotumumab for the treatment of active thyroid eye disease. More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks news, Read more .....
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...